Medical Affairs and Clinical Research

Clinical Research & Clinical Trials

Orphan drug designation provides key incentives of the ODA, including significant tax credits for qualified clinical testing. The BBCR team will empower sponsors with medical insight, ODA application experience, strategic clinical plan, and streamlined trials design.

October 12th, 2022 | Medical Affairs and Clinical Research

Developing drugs with substantial benefits in smaller, molecularly defined, pharmacologically relevant subpopulations of patients with the same clinically recognized disease is increasingly being viewed as a viable pathway for bringing drugs to market.    

BBCR supports innovative and repurposing treatments for orphan diseases.

October 4th, 2022 | Medical Affairs and Clinical Research

Developing innovative or repurposing drugs for orphan diseases can be rewarding, but navigating the challenges is not for the faint of heart. Expert guidance is essential in an area where patients are few; a lack of previous studies may hamper progress as you mount an orphan petition and negotiate a clinical plan with the FDA. […]

BBCR provides expert development guidance for Orphan Disease. The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap.

September 28th, 2022 | Medical Affairs and Clinical Research

As one of the first consultancy teams to streamline clinical trials, BBCR’s boutique consulting team specializes in rare disease and orphan indications dedicated to supporting pharmaceutical innovators, and nurturing each product’s strengths. The BBCR Team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment Clinical strategy for […]

BBCR offers Translational Medicine and Biomarkers Program Consultation to bridge the gap between pre-clinical and early clinical development

September 21st, 2022 | Medical Affairs and Clinical Research

Translational medicine is a bridge between pre-clinical and early clinical development (from bench to bedside), creating the foundation for precision medicine in late clinical development. A translational medicine program includes the adoption of biomarkers to mitigate clinical trials risk, identify patient subpopulations, facilitate decision-making, and accelerate drugs’ market approval.  

The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap. Learn more about our services by visiting bbcrconsulting.com

September 20th, 2022 | Medical Affairs and Clinical Research

How we can help The BBCR team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment We offer clinical strategy for orphan diseases and precision medicine RWE can be used to build orphan diseases evidence to support regulatory decisions BBCR serves small and medium sized Biotech Companies, […]

BBCR regularly partners with small and medium sized drug and device biotechnology firms. Our clients are innovators and clinical researchers looking for a more efficient path to approval, and come to us from across the globe. Reach out today to learn more.

September 15th, 2022 | Medical Affairs and Clinical Research

The BBCR mission is to simplify clinical research, encourage cost-effective trials, and help innovators navigate through the regulatory process.   Small & Medium Sized Biotech Companies currently moving from pre-clinical studies toward clinical trials in need of interim Chief Medical Officer in need of regulatory strategy consultancy in need of preparing a pre-IND, orphan petition, IND, […]

BBCR specializes in strategy and early clinical research services from preclinical through Phase I and POC studies to enable informed, timely decision making for our clients.

August 31st, 2022 | Medical Affairs and Clinical Research

BBCR Consulting offers clinical, regulatory, translational, and biomarker consulting services that support our clients’ needs. Our process is designed to maximize time and cost efficiencies while mitigating risk. We partner with domestic and international companies. Our mission is to support pharma and biotech companies, and nurture their products’ strengths while improving efficiency and safety.  

BBCR’s experienced CRO Management and Drug development team identify study remediation strategies and provide a resource for any Study Rescue

August 23rd, 2022 | Medical Affairs and Clinical Research

Every clinical study has its unique challenges that initially may not have been factored for, presenting the need for study remediation and rescue. Experienced management can help sponsors to address prolonged trial timeline and high quality data. Rare Diseases and Precision Medicine Require Unique Approaches In Clinical Trial Design. There could be any number of […]

An attractive option of drug repurposing is to use a scientific approach to identify new uses for existing drugs thereby reducing the need for early stage clinical trials.

August 17th, 2022 | Medical Affairs and Clinical Research

People tend to believe that a repurposed therapy can never be truly novel or transformative. Nothing could be further from the truth. About a third of orphan approvals by the FDA since the program began have been mostly for repurposed mass-market drugs. BBCR’s team of industry experts can help match treatments to rare genetic conditions […]

BBCR meets clients’ needs in the fast paced and ever-changing regulatory environment. As specialists in Orphan and Personalized Medicine, BBCR helps clients identify areas of need or economic interest and helps them find homes for treatments for rare diseases and precision medicine.

August 10th, 2022 | Medical Affairs and Clinical Research

BBCR helps orphan drug developers find direction in clinical trials involving biologics, biosimilars, small molecules, medical devices, and repurposing. BBCR consultants have the experience to guide you through the development process with a clinical plan and a regulatory strategy. Our team will empower you with medical insight, effective regulatory expertise, strategy, and streamlined early clinical […]

Pin It on Pinterest